Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance

P Koehler, M Bassetti, A Chakrabarti… - The Lancet Infectious …, 2021 - thelancet.com
Severe acute respiratory syndrome coronavirus 2 causes direct damage to the airway
epithelium, enabling aspergillus invasion. Reports of COVID-19-associated pulmonary …

The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin

M Hoenigl, R Sprute, M Egger, A Arastehfar… - Drugs, 2021 - Springer
The epidemiology of invasive fungal infections is changing, with new populations at risk and
the emergence of resistance caused by the selective pressure from increased usage of …

A marine microbiome antifungal targets urgent-threat drug-resistant fungi

F Zhang, M Zhao, DR Braun, SS Ericksen… - Science, 2020 - science.org
New antifungal drugs are urgently needed to address the emergence and transcontinental
spread of fungal infectious diseases, such as pandrug-resistant Candida auris. Leveraging …

Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections

KJ Shaw, AS Ibrahim - Journal of Fungi, 2020 - mdpi.com
Fosmanogepix is a first-in-class antifungal currently in Phase 2 clinical trials for the treatment
of invasive fungal infections caused by Candida, Aspergillus and rare molds. Fosmanogepix …

[PDF][PDF] Hope on the horizon: novel fungal treatments in development

AM Rauseo, A Coler-Reilly, L Larson… - Open Forum Infectious …, 2020 - academic.oup.com
The treatment of invasive fungal infections remains challenging due to limitations in currently
available antifungal therapies including toxicity, interactions, restricted routes of …

Pharmacodynamics, mechanisms of action and resistance, and spectrum of activity of new antifungal agents

NP Wiederhold - Journal of Fungi, 2022 - mdpi.com
Several new antifungals are currently in late-stage development, including those with novel
pharmacodynamics/mechanisms of action that represent new antifungal classes …

A comprehensive overview of the medicinal chemistry of antifungal drugs: perspectives and promise

KC Howard, EK Dennis, DS Watt… - Chemical Society …, 2020 - pubs.rsc.org
The emergence of new fungal pathogens makes the development of new antifungal drugs a
medical imperative that in recent years motivates the talents of numerous investigators …

Treatment of Cryptococcal meningitis: how have we got here and where are we going?

NTT Ngan, B Flower, JN Day - Drugs, 2022 - Springer
Cryptococcal meningitis is a devastating brain infection cause by encapsulated yeasts of the
Cryptococcus genus. Exposure, through inhalation, is likely universal by adulthood, but …

Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease

M Hoenigl, A Arastehfar, MC Arendrup… - Clinical Microbiology …, 2024 - Am Soc Microbiol
Fungal infections are on the rise, driven by a growing population at risk and climate change.
Currently available antifungals include only five classes, and their utility and efficacy in …

Aspergillus fumigatus and aspergillosis: From basics to clinics

A Arastehfar, A Carvalho, J Houbraken… - Studies in …, 2021 - ingentaconnect.com
The airborne fungus Aspergillus fumigatus poses a serious health threat to humans by
causing numerous invasive infections and a notable mortality in humans, especially in …